Immunome Inc (IMNM) 19.81 USD (+0.03%) | Healthcare NASDAQ

Immunome Inc. is a biopharmaceutical company specializing in the discovery and development of antibodies for the treatment of cancer and infectious diseases.

Price history of Immunome Inc

Performance & Momentum

6 Months 1.39 %

1 Year 119.62 %

3 Years 283.91 %

5 Years 3.32 %

Momentum

Unlock this indicator

Strategic Analysis

Immunome Inc • 2026

Immunome is positioned as a development-stage biotech focused on therapeutic antibodies and targeted oncology treatments. Its stock appeal rests on a highly optional platform, capable of quickly re-rating on clinical progress or partnerships, but with the typical profile of a company still dependent on scientific execution.

Strengths

Clear positioning in oncology, a segment where medical needs remain high and opportunities for differentiation are significant.
Specialized approach centered on therapeutic antibodies, an attractive technological angle for creating value in the event of clinical success or licensing.
Solid stock momentum, indicating renewed market interest in the company and a favorable perception of its growth potential.

Weaknesses

Development-stage biotech profile exposed to clinical, regulatory, and financing risk, as is typical for companies without mature revenue streams.
More uneven long-term performance history, reflecting high volatility and strong dependence on catalysts.

Momentum

Momentum is clearly positive and reflects a constructive market trend, supported by very strong recent share performance and a clear reservoir of confidence in the growth thesis. For investors, this suggests a stock that is well oriented in the near term, but whose valuation remains driven mainly by expectations of clinical or strategic progress rather than recurring fundamentals.

Analysis performed yesterday